Axovant Sciences (AXON) Stock Rating Reaffirmed by JMP Securities

JMP Securities restated their buy rating on shares of Axovant Sciences (NASDAQ:AXON) in a research report sent to investors on Monday. They currently have a $6.00 price objective on the biotechnology company’s stock.

Several other brokerages have also recently commented on AXON. ValuEngine upgraded shares of Axovant Sciences from a hold rating to a buy rating in a research report on Thursday, November 1st. Zacks Investment Research upgraded shares of Axovant Sciences from a hold rating to a buy rating and set a $1.25 target price for the company in a research report on Monday, January 7th. Jefferies Financial Group upgraded shares of Axovant Sciences from a hold rating to a buy rating and set a $3.00 target price for the company in a research report on Monday, December 17th. Oppenheimer restated a hold rating on shares of Axovant Sciences in a research report on Sunday, November 11th. Finally, BidaskClub upgraded shares of Axovant Sciences from a strong sell rating to a sell rating in a research report on Tuesday, October 16th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the stock. Axovant Sciences currently has a consensus rating of Hold and a consensus price target of $4.25.

Shares of AXON stock opened at $1.22 on Monday. The stock has a market cap of $157.74 million, a P/E ratio of -0.59 and a beta of 1.21. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 1.24. Axovant Sciences has a 52 week low of $0.93 and a 52 week high of $6.59.

Axovant Sciences (NASDAQ:AXON) last announced its earnings results on Thursday, February 7th. The biotechnology company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). On average, research analysts forecast that Axovant Sciences will post -1.25 EPS for the current year.

In related news, major shareholder Svf Investments (Uk) Ltd acquired 10,000,000 shares of the stock in a transaction that occurred on Tuesday, December 18th. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $10,000,000.00. Following the transaction, the insider now directly owns 99,285,714 shares in the company, valued at $99,285,714. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.00% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in Axovant Sciences by 60.5% during the 3rd quarter. Renaissance Technologies LLC now owns 2,091,700 shares of the biotechnology company’s stock worth $5,062,000 after purchasing an additional 788,100 shares in the last quarter. BlackRock Inc. increased its position in Axovant Sciences by 13.5% in the 3rd quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock valued at $3,447,000 after acquiring an additional 169,918 shares during the period. Hudson Bay Capital Management LP increased its position in Axovant Sciences by 23.8% in the 4th quarter. Hudson Bay Capital Management LP now owns 1,250,000 shares of the biotechnology company’s stock valued at $1,245,000 after acquiring an additional 240,000 shares during the period. Monashee Investment Management LLC acquired a new position in Axovant Sciences in the 4th quarter valued at approximately $996,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in Axovant Sciences by 12.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock valued at $1,354,000 after acquiring an additional 64,152 shares during the period. Institutional investors and hedge funds own 7.58% of the company’s stock.

About Axovant Sciences

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Read More: Price-Sales Ratio

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply